Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AcelRx Pharmaceuticals Inc presents ARX-04 dose-finding phase two study data at Anesthesia Medical Conference


Friday, 13 Dec 2013 07:30am EST 

AcelRx Pharmaceuticals Inc:Says it has presented additional detail from the Phase two dose-finding study of ARX-04, an investigational single-dose sublingual sufentanil NanoTab for moderate-to-severe acute pain, for which topline results were reported in April 2013.Says patients treated with the 30 mcg dose of sufentanil showed a rapid onset of action with a statistically significant beneficial difference in pain relief (p <0.001) and pain intensity (p <0.01) seen at 30 minutes after dosing compared to placebo.Says Dosing averaged every 2.4 hours over the duration of the 12-hour study.Says in addition, patient global assessment of the 30 mcg dose at 12 hours was superior to placebo (p=0.002) with 43.6% vs. 5.0% of the patients responding good or excellent for overall pain control.Says the 20 mcg dose was not significant for either endpoint.Says this study was funded by a grant from the U.S. Army Medical Research and Materiel Command.Says these results are being presented at the 67th Annual PostGraduate Assembly in Anesthesia being held in New York City. 

Company Quote

6.74
0.05 +0.75%
19 Dec 2014